These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 34289749)
1. Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar. Goyal P; Iyer J; Adhikary L; Vats B; Kabadi P; Pai H; Ranayhossaini D; Gouda S; Subbarao M; Mehta G; Saha A; Bera A; Sahu A; Kaur M; Singh A; Marwah A; Reddy Moole PK; Smith J; Melarkode R; Ullanat R Future Med Chem; 2021 Sep; 13(18):1531-1557. PubMed ID: 34289749 [No Abstract] [Full Text] [Related]
2. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin Chen X; Li C; Ewesuedo R; Yin D Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945 [TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab. Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514 [TBL] [Abstract][Full Text] [Related]
4. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers. Zhou H; Cao S; Zhu X; Xie J; Fan L; Ge Q; Wang Y; Zhu J; Liu Y; Shao Z; Shan R; Liu B; Wang H; Ding L Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):997-1003. PubMed ID: 32847423 [TBL] [Abstract][Full Text] [Related]
5. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. Wang J; Niu S; Dong W; Wei L; Ou L; Zhang T; Zhang L; Nie X; Wang Q; Shen T; Wang Q; Xia L; Liu G; Jin J; Zheng Q; Song H; Fang Y Expert Opin Investig Drugs; 2020 Jul; 29(7):755-762. PubMed ID: 32594779 [TBL] [Abstract][Full Text] [Related]
6. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980 [TBL] [Abstract][Full Text] [Related]
7. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects. Zhu X; Ding Y; Yu Y; Wang M; Zhou W; Wang J; Zhu X; Zhang H; Wang M; Chai K; Zhang X; Luk A; Jiang W; Liu S; Zhang Q Cancer Chemother Pharmacol; 2021 Mar; 87(3):349-359. PubMed ID: 33169186 [TBL] [Abstract][Full Text] [Related]
8. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. Alexeev SM; Khorinko AV; Mukhametshina GZ; Shelepen KG; Burdaeva ON; Kulik SA; Satheesh CT; Srivastava K; Vikranth M; Kryukov F; Paltusova AN; Shustova MS; Ivanov RA BMC Cancer; 2020 Aug; 20(1):783. PubMed ID: 32819305 [TBL] [Abstract][Full Text] [Related]
9. [Biosimilars in oncology. Focus on SB3 studies.]. Del Re M; Del Mastro L Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial. Esteva FJ; Baranau YV; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskiy D; Pikiel J; Eniu AE; Li RK; Rusyn AV; Tiangco B; Lee SJ; Lee SY; Yu SY; Stebbing J Cancer Chemother Pharmacol; 2019 Oct; 84(4):839-847. PubMed ID: 31428820 [TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects. Farmahini Farahani M; Maghzi P; Jafari Aryan N; Payandemehr B; Soni M; Azhdarzadeh M Expert Opin Investig Drugs; 2020 Dec; 29(12):1443-1450. PubMed ID: 33016783 [TBL] [Abstract][Full Text] [Related]
12. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. Esteva FJ; Stebbing J; Wood-Horrall RN; Winkle PJ; Lee SY; Lee SJ Cancer Chemother Pharmacol; 2018 Mar; 81(3):505-514. PubMed ID: 29330636 [TBL] [Abstract][Full Text] [Related]
16. Trastuzumab biosimilar shows potential for breast cancer. Baker H Lancet Oncol; 2017 Jan; 18(1):e4. PubMed ID: 27956154 [No Abstract] [Full Text] [Related]
17. Clinical development of CT-P6 in HER2 positive breast cancer. Fu C; Stebbing J; Esteva FJ Expert Opin Biol Ther; 2019 Oct; 19(10):987-992. PubMed ID: 31507219 [No Abstract] [Full Text] [Related]
18. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment. Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280 [TBL] [Abstract][Full Text] [Related]
19. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer. Paplomata E; Nahta R Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568 [TBL] [Abstract][Full Text] [Related]
20. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. McBride A; MacDonald K; Fuentes-Alburo A; Abraham I J Med Econ; 2021; 24(1):743-756. PubMed ID: 34003067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]